A Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Enzalutamide in Participants With Metastatic Castration-Resistant Prostrate Cancer (mCRPC) After Failure of an Androgen Synthesis Inhibitor And Failure of, Ineligibility For, or Refusal of a Taxane Regimen
Clinical trial NCT03016312 · COMPLETED
Trial details
- NCT number
- NCT03016312
- Sponsor
- Hoffmann-La Roche
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2017-01-10
- Primary completion
- 2019-06-24
- Enrollment
- 759
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.